{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:07:35Z","timestamp":1771657655644,"version":"3.50.1"},"reference-count":40,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy Bucharest, Romania","award":["33PFE\/30.12.2021"],"award-info":[{"award-number":["33PFE\/30.12.2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: During the last two years, the COVID-19 pandemic led to millions of disease-related deaths worldwide. The efforts of the scientific community facing this global challenge resulted in outstanding achievements. Thus, within one year, new mRNA-based vaccines against SARS-CoV-2 viral infection were released, providing highly efficient protection and showing a very good safety profile in the general population. However, clinical data collection after vaccination is a continuous process for the long-term safety of any new medical product. The aim of our paper is to present two cases of hematological malignancies: diffuse large B-cell non-Hodgkin lymphoma and T\/NK-cell lymphoma, diagnosed shortly after the administration of the mRNA COVID-19 vaccine. Methods and Results: Case 1: A female patient was admitted with a suspicious cervical mass that emerged within one week after the administration of second dose of the BNT162b2 COVID-19 vaccine. Surgical removal followed by pathology assessment of the specimen confirmed the diagnosis of diffuse large B-cell non-Hodgkin lymphoma. Case 2: A male patient was admitted with multiple ulcerative oral lesions arising on the third day after the initial dose of the BNT162b2 COVID-19 vaccine. These lesions had a progressive character and during the following months were complicated with repetitive episodes of heavy oral bleeding, requiring blood transfusions. The incisional biopsy of the lesions and pathological assessment of the specimens confirmed the diagnosis of T\/NK-cell lymphoma. Conclusions: The safety profile of the mRNA-based vaccines is an undeniable fact. In most cases, suspicions of potentially aggressive side effects were ruled out, proving to be transient post-vaccine reactions. Clinicians should remain alert to report any potentially aggressive manifestations emerging in the context of mRNA COVID-19 vaccination, such as these cases of hematological malignancies, in order to promote additional investigations on the particular mechanisms of action of COVID-19 vaccines and to provide the best medical care to the patients.<\/jats:p>","DOI":"10.3390\/medicina58070874","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:21:50Z","timestamp":1656634910000},"page":"874","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7949-030X","authenticated-orcid":false,"given":"Maria-Alexandra","family":"Zamfir","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, \u201cCarol Davila\u201d Central Military Emergency Hospital, 010825 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Moraru","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, \u201cCarol Davila\u201d Central Military Emergency Hospital, 010825 Bucharest, Romania"},{"name":"Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, \u201cTitu Maiorescu\u201d University, 031593 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia","family":"Dobrea","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Department of Hematology, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea-Elena","family":"Scheau","sequence":"additional","affiliation":[{"name":"Department of Radiology and Medical Imaging, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Iacob","sequence":"additional","affiliation":[{"name":"Pathology Laboratory Personal Genetics, 010987 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-6427","authenticated-orcid":false,"given":"Cosmin","family":"Moldovan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cTitu Maiorescu\u201d University, 031593 Bucharest, Romania"},{"name":"General Surgery Ward, Witting Clinical Hospital, 010243 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7676-6393","authenticated-orcid":false,"given":"Cristian","family":"Scheau","sequence":"additional","affiliation":[{"name":"Department of Physiology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-7965","authenticated-orcid":false,"given":"Constantin","family":"Caruntu","sequence":"additional","affiliation":[{"name":"Department of Physiology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Dermatology, \u201cProf. N.C. Paulescu\u201d National Institute of Diabetes, Nutrition and Metabolic Diseases, 011233 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4200-3069","authenticated-orcid":false,"given":"Ana","family":"Caruntu","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, \u201cCarol Davila\u201d Central Military Emergency Hospital, 010825 Bucharest, Romania"},{"name":"Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, \u201cTitu Maiorescu\u201d University, 031593 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"ref_1","unstructured":"(2022, May 04). WWHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13037-021-00291-9","article-title":"The safety of COVID-19 mRNA vaccines: A review","volume":"15","author":"Anand","year":"2021","journal-title":"Patient Saf. Surg."},{"key":"ref_3","unstructured":"Ma, J. (2022, May 04). Coronavirus: China\u2019s First Confirmed COVID-19 Case Traced Back to November 17. Available online: https:\/\/www.scmp.com\/news\/china\/society\/article\/3074991\/coronavirus-chinas-first-confirmed-covid-19-case-traced-back."},{"key":"ref_4","unstructured":"FDA News Release (2022, May 04). FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19."},{"key":"ref_5","unstructured":"FDA News Release (2022, May 04). FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41591-021-01454-y","article-title":"COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries","volume":"27","author":"Warren","year":"2021","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing COVID-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijid.2021.04.047","article-title":"Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers","volume":"106","author":"Kadali","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.6004\/jnccn.2021.7113","article-title":"Adverse Events Reported by Patients with Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine","volume":"20","author":"Shulman","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_13","unstructured":"Shroff, R.T., Chalasani, P., Wei, R., Pennington, D., Quirk, G., Schoenle, M.V., Peyton, K.L., Uhrlaub, J.L., Ripperger, T.J., and Jergovi\u0107, M. (2021). Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy. MedRxiv, 21257129. Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/34013289."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.17743","article-title":"Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients","volume":"195","author":"Benda","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv."},{"key":"ref_16","first-page":"e91","article-title":"Recurrence of cutaneous T-cell lymphoma post viral vector COVID-19 vaccination","volume":"36","author":"Panou","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3389\/fmed.2021.798095","article-title":"Rapid progression of angioimmunoblastic T Cell lymphoma following BNT162b2 mRNA vaccine booster shot: A case report","volume":"8","author":"Goldman","year":"2021","journal-title":"Front. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13543784.2021.1855140","article-title":"Investigational drugs for the treatment of diffuse large B-cell lymphoma","volume":"30","author":"Patriarca","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2020.05.010","article-title":"The global impact of the coronavirus pandemic","volume":"53","author":"Hiscott","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_20","unstructured":"(2022, May 04). Coronavirus Disease (COVID-19) Pandemic. Available online: https:\/\/www.euro.who.int\/en\/health-topics\/health-emergencies\/coronavirus-covid-19\/novel-coronavirus-2019-ncov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112527","DOI":"10.1016\/j.biopha.2021.112527","article-title":"Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines","volume":"146","author":"Zinatizadeh","year":"2022","journal-title":"Biomed Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wu, Q., Dudley, M.Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D., and Yu, H. (2021). Evaluation of the safety profile of COVID-19 vaccines: A rapid review. BMC Med., 19.","DOI":"10.1186\/s12916-021-02059-5"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bettini, E., and Locci, M. (2021). SARS-CoV-2 mRNA Vaccines: Immunological mechanism and beyond. Vaccines, 9.","DOI":"10.3390\/vaccines9020147"},{"key":"ref_27","unstructured":"Vogel, A.B., Kanevsky, I., Che, Y., Swanson, K.A., Muik, A., Vormehr, M., Kranz, L.M., Walzer, K.C., Hein, S., and G\u00fcler, A. (2020). A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. BioRxiv, 280818. Available online: http:\/\/biorxiv.org\/content\/early\/2020\/09\/08\/2020.09.08.280818.abstract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gagelmann, N., Passamonti, F., Wolschke, C., Massoud, R., Niederwieser, C., Adjall\u00e9, R., Mora, B., Ayuk, F., and Kr\u00f6ger, N. (2021). Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: A systematic review and meta-analysis. Haematologica.","DOI":"10.2139\/ssrn.3929967"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1080\/10428194.2021.1924371","article-title":"Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination","volume":"62","author":"Brumfiel","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S0959-8049(21)00755-3","article-title":"Cutaneous T-cell lymphoma (CTCL) exacerbation after viral vector COVID-19 vaccination","volume":"156","author":"Panou","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tang, W.R., Hsu, C.W., Lee, C.C., Huang, W.L., Lin, C.Y., Hsu, Y.T., Chang, C., Tsai, M.T., Hu, Y.N., and Hsu, C.H. (2021). A Case Report of Posttransplant Lymphoproliferative Disorder after AstraZeneca Coronavirus Disease 2019 Vaccine in a Heart Transplant Recipient. Transplant. Proc.","DOI":"10.1016\/j.transproceed.2021.09.006"},{"key":"ref_34","first-page":"e13524","article-title":"Lymphadenopathy Associated with the COVID-19 Vaccine","volume":"13","author":"Hiller","year":"2021","journal-title":"Cureus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jha2.265","article-title":"Lymphadenopathy with florid lymphoid and Langerhans cell hyperplasia and hemophagocytosis mimicking lymphoma after COVID-19 mRNA vaccination","volume":"2","author":"Tintle","year":"2021","journal-title":"Ejhaem"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jha2.297","article-title":"Axillary lymph nodes on PET in Hodgkin lymphoma after COVID-19 vaccination","volume":"2","author":"Arens","year":"2021","journal-title":"Ejhaem"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mazur, M., Du\u015b-Ilnicka, I., Jedli\u0144ski, M., Ndokaj, A., Janiszewska-Olszowska, J., Ardan, R., Radwan-Oczko, M., Guerra, F., Luzzi, V., and Vozza, I. (2021). Facial and oral manifestations following covid-19 vaccination: A survey-based study and a first perspective. Int. J Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18094965"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Riad, A., Pokorn\u00e1, A., Attia, S., Klugarov\u00e1, J., Ko\u0161\u010d\u00edk, M., and Klugar, M. (2021). Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071428"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Manfredi, M., Ghidini, G., Ridolo, E., and Pizzi, S. (2021). Oral lesions postinjection of the first administration of Pfizer-BioNTech SARS-CoV-2 (BNT162b2) vaccine. Oral Dis.","DOI":"10.1111\/odi.13912"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jormas.2022.01.013","article-title":"Ulcers on the bilateral palate mucosa following mRNA-based vaccination for coronavirus disease 2019 (COVID-19): A case report","volume":"123","author":"Maeda","year":"2022","journal-title":"J. Stomatol. Oral Maxillofac. Surg."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/7\/874\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:40:47Z","timestamp":1760139647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/7\/874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["medicina58070874"],"URL":"https:\/\/doi.org\/10.3390\/medicina58070874","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}